Skip to main content

China Pharma Holdings, Inc.

corporate_fare Company Profile

China Pharma Holdings, Inc.

CPHI·NYSE·Life Sciences·CIK 0001106644

China Pharma Holdings, Inc. is a Nevada holding company whose operations are conducted entirely in the People's Republic of China through its wholly owned subsidiary, Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson"), and Helpson's subsidiaries. China Pharma is not a Chinese operating company. Through Helpson, the company is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All operations are conducted in the PRC, where the manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of Helpson's pharmaceutical products are sold on a prescription basis, and all of them have been approved for at least one or more therapeutic indications by the National Medical Products Administration (NMPA, formerly China Food and Drug Administration, CFDA) based upon demonstrated safety and efficacy. As of December 31, 2025, China Pharma, through Helpson, is granted rights to manufacture 19 pharmaceutical products for a wide variety of diseases and medical indications. Each product may be classified into one of three general categories: basic generic drugs, which are common drugs in the PRC for which there is a very large market demand; first-to-market generic drugs, which are generic drugs that are new to the PRC marketplace; or modern Traditional Chinese Medicines (TCMs), which are generally comprised of non-synthetic, plant-based medicinal compounds that have been widely used in the PRC for thousands of years. The company applies modern production techniques to produce pharmaceutical products in different formulations, such as tablets, capsules or powders.

China Pharma Holdings, Inc. (NYSE:CPHI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 3 items for CPHI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 8/10. Across its 3 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for CPHI spans 10-Q, DEF 14A, PRE 14A.

Recent high-impact activity:

  • China Pharma Q3 Loss Widens to $1.9M; Going-Concern Warning Reiterated
  • China Pharma Proxy: 1:50 Reverse Split Vote and 8.03M-Share Equity Plan Increase
  • China Pharma Seeks Up-to-1:50 Reverse Split and 8.0M-Share Equity Plan Increase

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$4.14M
Net Income
-$3.19M
Diluted EPS
-$0.74
Op. Cash Flow
$148.26K
Free Cash Flow
$88.94K
Gross Profit
-$131.95K
Operating Income
-$3.24M
Cash & Equivalents
$345.11K
Total Debt
$1.44M
Debt / Equity
0.06×
Net Margin
-76.9%
Shares Outstanding
15.52M sh
Source: 10-K · filed 2026-04-01 · accession 0001213900-26-038521

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 89,473 shares in CPHI as of the October 30, 2026 settlement, a 54.9% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 20.6% of CPHI volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)89,473 shares as of October 30, 2026
Change vs prior period▼ 54.9%
Days to cover1.00 at avg daily volume of 192,428
Daily short volume (FINRA facilities)20.6% of 21,178 shares on November 20, 2026
5-day average short volume27.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.4384
52-week range · as of 2026-11-18 $0.3818 – $19.19
Market cap
$18.86M
Volume
32.9K (0.2× avg)
3-mo avg 182.4K
Live data · 2026-11-22 04:00 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CPHI - Latest Insights

CPHI
Nov 18, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.4885
Real-time Price: $0.4384 info
Change: -$0.0501 (-10%) info
Market Cap: $18.861M info
CPHI
Nov 10, 2026, 4:05 PM EST
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.551
Real-time Price: $0.4384 info
Change: -$0.1126 (-20%) info
Market Cap: $18.861M info
CPHI
Oct 30, 2026, 4:40 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.6102
Real-time Price: $0.4384 info
Change: -$0.1718 (-28%) info
Market Cap: $18.861M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets